Anke C. Schick-Reinacher

St Josef Hospital
Bochum, NW, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 137 publications

Suspected radiologic tumor progression in metastatic squamous cell carcinoma with an unexpected etiology

Suspected radiologic tumor progression in metastatic squamous cell carcinoma with an unexpected etiology

Journal: Pneumologie (Stuttgart, Germany)

Published: August 05, 2026

Consolidative Thoracic Radiotherapy With Atezolizumab Maintenance in Extensive-Stage Small Cell Lung Cancer: The Phase 2 TREASURE Randomized Clinical Trial (AIO-TRK-0320).

Consolidative Thoracic Radiotherapy With Atezolizumab Maintenance in Extensive-Stage Small Cell Lung Cancer: The Phase 2 TREASURE Randomized Clinical Trial (AIO-TRK-0320).

Journal: JAMA oncology

Published: July 09, 2026

Prognosis and aetiology of hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) in patients with active lung or lower head and neck cancer (PEPP-C): a retrospective, matched multicentre cohort study in Germany and Spain.

Prognosis and aetiology of hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) in patients with active lung or lower head and neck cancer (PEPP-C): a retrospective, matched multicentre cohort study in Germany and Spain.

Journal: Infection

Published: March 30, 2026

Atezolizumab plus FOLFOX for Stage III Mismatch Repair-Deficient Colon Cancer.

Atezolizumab plus FOLFOX for Stage III Mismatch Repair-Deficient Colon Cancer.

Journal: The New England journal of medicine

Published: March 25, 2026

Chemotherapy for patients with circulating tumour DNA-positive, stage II colon cancer (CIRCULATE)-an AIO/ABCSG trial.

Chemotherapy for patients with circulating tumour DNA-positive, stage II colon cancer (CIRCULATE)-an AIO/ABCSG trial.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: March 20, 2026

Fruquintinib in combination with tislelizumab versus trifluridine/tipiracil and bevacizumab in third-line and beyond MSS mCRC without active liver metastases-the IKF-080/AIO-QUINTIS trial.

Fruquintinib in combination with tislelizumab versus trifluridine/tipiracil and bevacizumab in third-line and beyond MSS mCRC without active liver metastases-the IKF-080/AIO-QUINTIS trial.

Journal: ESMO gastrointestinal oncology

Published: March 19, 2026

Medical information and decision-making in palliative cancer: a qualitative study of patients' perceptions, needs, and preferences regarding physician communication.

Medical information and decision-making in palliative cancer: a qualitative study of patients' perceptions, needs, and preferences regarding physician communication.

Journal: BMC palliative care

Published: March 13, 2026

Erratum: Benefit of Chemoradiotherapy Versus Chemotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer: The Randomized CONKO-007 Trial.

Erratum: Benefit of Chemoradiotherapy Versus Chemotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer: The Randomized CONKO-007 Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: January 08, 2026

First-line treatment efficacy of anti-EGFR versus anti-VEGF antibodies in BRAFV600E-mutated metastatic colorectal cancer according to primary tumor sidedness: A pooled analysis of seven clinical trials performed in the first-line treatment of mCRC (German AIO Study Group).

First-line treatment efficacy of anti-EGFR versus anti-VEGF antibodies in BRAFV600E-mutated metastatic colorectal cancer according to primary tumor sidedness: A pooled analysis of seven clinical trials performed in the first-line treatment of mCRC (German AIO Study Group).

Journal: European journal of cancer (Oxford, England : 1990)

Published: September 11, 2025

PROTECTOR / FIRE‑10: study protocol for a prospective, randomized, open-label, multicenter phase III trial to investigate the efficacy of preoperative systemic therapy in advanced colon cancer.

PROTECTOR / FIRE‑10: study protocol for a prospective, randomized, open-label, multicenter phase III trial to investigate the efficacy of preoperative systemic therapy in advanced colon cancer.

Journal: BMC cancer

Published: August 25, 2025

Benefit of Chemoradiotherapy Versus Chemotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer: The Randomized CONKO-007 Trial.

Benefit of Chemoradiotherapy Versus Chemotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer: The Randomized CONKO-007 Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: August 13, 2025

Interdisciplinary therapy of extremity soft tissue sarcomas: current evidence on systemic treatments and the role of reconstructive surgery.

Interdisciplinary therapy of extremity soft tissue sarcomas: current evidence on systemic treatments and the role of reconstructive surgery.

Journal: Innovative surgical sciences

Published: June 30, 2025

Showing 1-12 of 137

Last Updated: 09/26/2026